Drug intelligence / Profile preview

APH-091142

Development stage: Preclinical
Lead developer: Aphios
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

APH-091142 is an antibody-drug conjugate (ADC) being developed by Aphios for the treatment of breast cancer. The candidate is part of Aphios's oncology pipeline, which leverages proprietary SuperCritical Fluid (SCF) technology platforms for the manufacturing and formulation of complex biologics and drug delivery systems. As an ADC, APH-091142 is designed to provide targeted delivery of therapeutic agents to breast cancer cells, potentially improving efficacy and reducing systemic toxicity compared to traditional chemotherapy. Specific details regarding its molecular target, linker technology, and cytotoxic payload have not been publicly disclosed in the primary pipeline documentation.

Beyond the preview

Go deeper on APH-091142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-091142.

Explore the full profile